New Adopters of Telemedicine During the Coronavirus-19 Pandemic in Respondents to an Online Community Survey: The Case for Access to Remote Management Tools for Individuals with Chronic Obstructive Pulmonary Disease.
COVID-19
copd
exacerbations
telehealth
telemedicine
Journal
Chronic obstructive pulmonary diseases (Miami, Fla.)
ISSN: 2372-952X
Titre abrégé: Chronic Obstr Pulm Dis
Pays: United States
ID NLM: 101635411
Informations de publication
Date de publication:
27 Apr 2021
27 Apr 2021
Historique:
pubmed:
9
12
2020
medline:
9
12
2020
entrez:
8
12
2020
Statut:
ppublish
Résumé
To investigate telemedicine adoption, emergency department avoidance, and related characteristics of patients with chronic obstructive pulmonary disease (COPD) with and without exacerbations since the coronavirus 2019 (COVID-19) pandemic began. We conducted the second of a series of online surveys via SurveyMonkey.com of people with COPD between May 1, 2020 and May 31, 2020. Frequency, percentage, and Fisher's exact test (2-sided) were calculated using SPSS version 26. More than half of respondents (157, 64%), indicated that they started using telemedicine in 2020. A total of 47% of respondents reported having had at least 1 exacerbation since January 1, 2020. Respondents who had at least 1 exacerbation in 2020 were more likely to start using telemedicine in 2020 than respondents who did not report any exacerbation in 2020 (75.7% versus 54.3%, In response to social distancing and other COVID-19 precautions, people with COPD are avoiding traditional, in-person health care environments and turning to telemedicine to prevent and manage exacerbations. Further investigation is needed to identify best practices in and barriers to telemedicine in this population.
Identifiants
pubmed: 33291190
doi: 10.15326/jcopdf.2020.0181
pmc: PMC8237976
doi:
Types de publication
Journal Article
Langues
eng
Pagination
213-218Subventions
Organisme : AstraZeneca
Pays : United States
Organisme : GlaxoSmithKline
Pays : United States
Organisme : Teva
Pays : United States
Organisme : Mylan
Pays : United States
Organisme : Pfizer
Pays : United States
Informations de copyright
JCOPDF © 2021.
Références
Telemed J E Health. 2016 Feb;22(2):114-122
pubmed: 26259074
PLoS One. 2020 May 11;15(5):e0233147
pubmed: 32392262
Chronic Obstr Pulm Dis. 2019 Jul 24;6(3):210-220
pubmed: 31075813
Respir Med. 2018 Oct;143:91-102
pubmed: 30261999
Can Respir J. 2011 Jul-Aug;18(4):216-20
pubmed: 22059179
Chest. 2015 Jan;147(1):31-45
pubmed: 25058738
Am J Respir Crit Care Med. 2017 Feb 1;195(3):324-330
pubmed: 27556408